Who are Cloxazolazepam's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Lumigan, Aleve, Linolic Acid, Meclofenamate.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/cloxazolam.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Cloxazolazepam — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Cloxazolazepam (CLOXAZOLAM) competitive landscape: 4 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: cloxazolam. Area: Other.

phase 2 cloxazolam Aldo-keto reductase family 1 member C3 Other Small molecule Live · refreshed every 30 min

Target snapshot

Cloxazolazepam (CLOXAZOLAM). Cloxazolazepam works by inhibiting the enzyme Aldo-keto reductase family 1 member C3.

Comparator set (4 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Cloxazolazepam TARGET	CLOXAZOLAM		phase 2	cloxazolam	Aldo-keto reductase family 1 member C3
Lumigan	BIMATOPROST		marketed	Prostaglandin Analog [EPC]	Aldo-keto reductase family 1 member C3	2001-01-01
Aleve	naproxen	Generic (originally Syntex)	marketed	NSAID	Aldo-keto reductase family 1 member C2, Aldo-keto reductase family 1 member C3, Prostaglandin G/H synthase 1	1976-01-01
Linolic Acid	LINOLEIC ACID		marketed		Aldo-keto reductase family 1 member C3, Fatty acid-binding protein, adipocyte, Fatty acid-binding protein, heart
Meclofenamate	Meclofenamate	Memorial Sloan Kettering Cancer Center	marketed		Aldo-keto reductase family 1 member C1, Aldo-keto reductase family 1 member C2, Aldo-keto reductase family 1 member C3

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (cloxazolam class)

· 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Cloxazolazepam — Competitive Intelligence Brief. https://druglandscape.com/ci/cloxazolam. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing